• 1
    Radoja N, Komine M, Jho SH, Blumenberg M, Tomic-Canic M. Novel mechanism of steroid action in skin through glucocorticoid receptor monomers. Mol Cell Biol 2000;20:432839.
  • 2
    Schafer KM, Kleuser B, Ahmed M, Holtje HD, Korting HC. Glucocorticoids for human skin: New aspects of the mechanism of action. Skin Pharmacol Physiol 2005;18:10314.
  • 3
    Shah VP, Elkins J, Hanus J, Noorizadeh C, Skelly JP. In vitro release of hydrocortisone from topical preparations and automated procedure. Pharm Res 1991;8:559.
  • 4
    Mattek Corp. E.s.m. Available at: (accessed January 5, 2011).
  • 5
    Bronaugh RL, Stewart RF, Congdon ER. Methods for in vitro percutaneous absorption studies II: Animal models for human skin. Toxicol Appl Pharmacol 1982;62:4818.
  • 6
    Priborsky J, Muhlbachova E. Evaluation of in-vitro percutaneous absorption across human skin and in animal models. J Pharm Pharmacol 1990;42:46872.
  • 7
    Schmook FP, Meingassner JG, Billich A. Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int J Pharm 2001;215:516.
  • 8
    Shah VP, Elkins JS, and Williams RL. Evaluation of the test system used for in vitro release of drugs for topical dermatological drug products. Pharm Dev Technol 1999;4:37785.
  • 9
    Shah VP, Elkins JS. In vitro release from glucocorticosteroid ointments. J Pharm Sci 1995;84:113940.
  • 10
    Shah VP, Elkins JS, Lam SY, Skelly JP. Detemination of in vitro drug release from hydrocortisone creams. Int J Pharm 1989;53:539.
  • 11
    Sankar V, Praveen C, Prasanth KG, Srinivas CR, Ruckmann K. Formulation and evaluation of a proniosome hydrocortisone gel in comparison with a commercial cream. Pharmazie 2009;64:7314.
  • 12
    Wester RC, Maibach HI. In vitro testing of topical pharmaceutical formulation. In: BronaughRL, MaibachH, eds. Percutaneous absorption. 2nd edition. New York: Marcel Dekker; 1989:6539.
  • 13
    Brain KA, Walters KA, and Watkinson AC. Methods for studying percuteneous absorption. In: WaltersKA, ed. Dermatological and transdermal formulations. New York: Marcel Dekker; 2002:197270.
  • 14
    Netzlaff F, Lehr CM, Wertz PW, Schaefer UF. The human epidermis models EpiSkin, SkinEthic and EpiDerm: An evaluation of morphology and their suitability for testing phototoxicity, irritancy,corrosivity and substance transport. Eur J Pharm Biopharm 2005;60:16778.
  • 15
    Chatterjee A, Babu RJ, Klausner M, Singh M. In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDerm™ (EPI-200) cultured human skin and hairless rats. Toxicol Lett 2006;167:8594.
  • 16
    Gohel MC, Panchal MK, Jogani VV. Novel mathematical method for quantitative expression of deviation from the higuchi model. AAPS PharmSciTech 2000;1.
  • 17
    Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961;50:8745.
  • 18
    Elias PM, Cooper ER, Korc A, and Brown BE. Percutaneous transport in relation to stratum corneum structure and lipid composition. J Invest Dermatol 1981;76:297301.
  • 19
    Hadgraft J, Guy RH. Feasibility assessment in topical and transdermal delivery: Mathematical models and in vitro studies. In: GuyR, HadgraftJ, eds. Transdermal drug delivery. 2nd edition. New York: Marcel Dekker; 2003:123.
  • 20
    Sinko PJ. Diffusion. In: SinkoPJ, ed. Martin's physical pharmacy and pharmaceutical sciences. 5th edition. Lippincott Williams & Wilkins; 2006:30135.
  • 21
    Frankfort-Nachmias C, Leon-Guerrero A. Analysis of variance: ANOVA for multiple linear regression. In: Social statistics for a diverse society. 5th edition. Thousand Oaks CA: Pine Forge Press, an Imprint of SAGE Publications. Inc; 2009:4934.
  • 22
    Bamba FL, Wepierre J. Role of the appendageal pathway in the percutaneous absorption of pyridostigmine bromide in various vehicles. Eur J Drug Metab Pharmacokinet 1993;18:33948.